Saturday, 31 October 2026European Markets

JCDECAUX Stock Went Down By Over 11% At Session Start On Thursday

Loading stream...

(vianews) - shares of jcdecaux (cac 40: dec.pa) fell by a staggering 11.24% to €20.22 at 10:58 est on thursday, after two successive sessions in a row of losses. cac 40 is sliding 0.54% to €7,285.20, after two consecutive sessions in a row of losses. this seems, up until now, a somewhat bearish trend trading session today.

about jcdecaux

jcdecaux se engages in the outdoor advertising activities worldwide. it operates through three segments: street furniture, transport, and billboard. the street furniture segment is involved in advertising in shopping malls; renting of street furniture; selling and renting of equipment; and the provision of cleaning, maintenance, and other activities. the transport segment provides advertising services in public transport systems, such as airports, metros, buses, tramways, and trains. the billboard segment is involved in advertising on private property, including traditional large format or back-light billboards; and the provision of neon-light billboards and advertising wraps. the company was founded in 1964 and is based in neuilly-sur-seine, france. jcdecaux se is a subsidiary of jcdecaux holding sas.

earnings per share

as for profitability, jcdecaux has a trailing twelve months eps of €-2.84.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, jcdecaux's stock is considered to be overbought (>=80).

more news about jcdecaux (dec.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com